Patent ID: 8338485
Filing Date: 2012-12-25
Classification: A61K,A61P,Y02A

Abstract:
1. A solid pharmaceutical composition in a unit dosage form for oral administration comprising: (a) an extended release formulation of 22.5 to 30 mg memantine or pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in concentration of memantine as a function of time (dC/dT) that is: (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine; and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; and wherein dC/dT is measured in a single-dose human PK study; and (b) a therapeutically effective amount of immediate release donepezil.